RxDoctor Payments Data

Edmund Schoeffler, MD

Gynecology · Richmond, VANPI 1366427577

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 97.8% of the total across 105 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 27 manufacturers reported payments, led by AbbVie at 30.3% of the total.

$2,400in general payments, 2019–2025

Across 105 payments — averaging $22.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$728
  • Myovant Sciences Inc.$201
  • Sumitomo Pharma America, Inc.$199
  • Mayne Pharma Commercial LLC$176
  • Coopersurgical, Inc.$163
  • Bayer$150
  • plus $784 from 21 others

What the payments were for

  • Food & beverage$2,34798%
  • Education$542%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,400 in reported general payments places this provider in the 80th percentile of 71 gynecology providers in Virginia.

See all gynecology providers in Virginia

Medicare billing

Part B allowed, 2024
$197,216
Medicare patients
1,106
Services billed
6,262

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
PremarinEstrogens, Conjugated18$8,833
Estradiol94$4,946
PremproEstrogen,con/M-Progest Acet12$2,851
Raloxifene Hcl68$2,524
Alendronate Sodium254$1,823
YuvafemEstradiol22$1,810
Ibandronate Sodium32$1,525
Metronidazole26$917
ValacyclovirValacyclovir Hcl21$620
Terconazole14$369
Medroxyprogesterone Acetate20$294
Fluconazole43$270
Nystatin14$156
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst13$140
Ciprofloxacin Hcl15$75

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerPremarin, Prempro$16$11,68430 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 71 gynecology providers in Virginia.

Other gynecology in Richmond

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →